Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers
Kasey Cox, Cody Weston, Moss Herberholz, Nicolas G. Glynos, Nicholas Kolbman, Julie Barron, Kevin F. Boehnke, Christopher W Fields, Daniel J. Kruger
Frontiers in Psychiatry August 4, 2023 DOI: 10.3389/fpsyt.2023.1224551 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Sample size | 1,221 |
| Population | Adults reporting psychedelic use recruited through a psychedelics advocacy event and social media |
| Topics | Psilocybin |
| Keywords | Confidentiality Health care Disconnection Hallucinogen Clinical psychology |
| Key findings | Psychedelic use is largely disconnected from primary and psychiatric clinical care, with low disclosure rates and a gap between desire for and receipt of therapist support. |
Abstract
Introduction: There is substantial public interest in psychedelics as potential treatments for psychiatric conditions. However, most psychedelics are criminalized under federal law in the USA, so it is unclear whether use occurs with clinical support. Our objective was to assess whether naturalistic psychedelic use occurs with clinical support, interactions between those using psychedelics and healthcare providers (psychiatrist, therapist, or primary physicians), and use characteristics.
Methods: We conducted an online, anonymous, confidential, cross-sectional survey of adults reporting psychedelic use ( N = 1221) through a psychedelics advocacy event and social media between 9/18/2022 and 11/5/2022. We assessed participant disclosure of psychedelic use with their psychiatric care provider (PsyCP) and/or primary care provider (PCP), desire for provider support, access to support, and rate of taking prescribed psychoactive medications alongside psychedelics.
Results: Among participants with such care providers, 22% disclosed psychedelic use to their PCP vs. 58% to their PsyCP. Participants were less confident in PCP vs. PsyCP ability to integrate psychedelics into treatment. Common reasons for nondisclosure included stigma, inadequate provider knowledge, and legal concerns. 23% reported taking psychedelics on the same day as potentially interacting psychiatric medications (e.g., anxiolytics, antidepressants). Despite 81% of participants desiring therapist support during psychedelic experiences, only 15% had received such support.
Discussion: Our results show that psychedelic use is generally disconnected from primary and psychiatric clinical care. This disconnection may result in safety issues, including inadequate screening for contraindicated conditions, lack of support during emergent adverse events, and drug interactions. Enhanced clinical education and orienting drug policy towards known harms and benefits of psychedelics is needed.
Comparable studies
Other cross-sectional and survey studies on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Individuals who had consumed psilocybin mushrooms and experienced a psychologically... | 2016 | Cross-sectional survey | n = 1,993 |
| The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms Internet survey respondents reporting challenging experiences with psilocybin | 2016 | Questionnaire development and validation | |
| Psychedelics and Mental Health: A Population Study Adult population in the United States | 2013 | Cross-sectional survey | n = 130,152 |
| Cessation and reduction in alcohol consumption and misuse after psychedelic use Individuals with prior alcohol use disorder who reported cessation or reduction in... | 2019 | Cross-sectional survey | n = 343 |
| Patterns of simultaneous polysubstance use in drug using university students Drug-using university students | 2006 | Cross-sectional survey | n = 149 |
Citations in the library
Cited by 24
- State Cannabis and Psychedelic Legislation and Microdosing Interest in the US. JAMA Health Forum June 7, 2024
- Psychedelic iatrogenic structural dissociation: an exploratory hypothesis on dissociative risks in psychedelic use. Frontiers in Psychology March 4, 2025
- Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts Journal of Psychoactive Drugs September 13, 2024
- UK medical students’ self-reported knowledge and harm assessment of psychedelics and their application in clinical research: a cross-sectional study BMJ Open March 1, 2024
- Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers Australian & New Zealand Journal of Psychiatry July 15, 2025
and 19 more in the library
Cites 30
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
and 25 more in the library